Acute Kidney Injury Treatment Market Size to Exceed USD 3.43 Bn by 2032

The Acute Kidney Injury Treatment Market, estimated at USD 1.96 Bn in 2025, is expected to exhibit a CAGR of 8.3% and reach USD 3.43 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Market Dynamics:

Rising prevalence of chronic diseases and growing geriatric population can drive the global acute kidney injury treatment market growth. It is estimated that over 30% of the global population will be aged over 60 years by 2050. This age group is more prone to develop chronic diseases such as diabetes, hypertension, and heart diseases - all of which are significant risk factors for AKI. Increasing focus of pharmaceutical companies on developing novel drugs for AKI treatment can drive the market growth over the forecast period. Several pipeline drugs are in various stages of clinical trials, which once approved will provide lucrative growth opportunities.

Increasing prevalence of chronic diseases can drive the market growth

Rising prevalence of chronic diseases such as diabetes, hypertension and cardiovascular diseases can drive the market growth. These chronic conditions are major risk factors for acute kidney injury. According to WHO, the number of people with diabetes has increased from 108 million in 1980 to 422 million in 2014.  Global burden of hypertension has also increased significantly in the past few decades. Acute kidney injury often occurs in people with pre-existing chronic kidney disease or other co-morbidities. As the incidence of chronic illnesses increases worldwide, the risk of developing acute renal failure also increases, thus, boosting demand for effective treatment options.

Growing geriatric population can boost market expansion

Age is one of the strongest risk factors for acute kidney injury. The kidneys deteriorate with age, making elderly people more susceptible to renal damage. The world population aged 60 years and above is projected to double from 12% to 22% between 2015 and 2050. The number of people aged 80 years or over is expected to triple from 125 million to 434 million over the same period. As aged people are more likely to develop acute kidney injury due to age-related physiological changes and co-morbid medical conditions, rising geriatric demographic present massive growth opportunities for the market players.

Lack of disease awareness hampers the market growth

Despite being a major cause of morbidity and mortality worldwide, acute kidney injury remains under-recognized globally. Many patients and primary care physicians often overlook early signs and symptoms of acute renal impairment. This is primarily because acute kidney injury commonly presents non-specifically and may go unnoticed in clinical settings. Moreover, people generally lack awareness about risk factors and preventive measures. Failure to promptly identify and treat acute renal damage often leads to poor clinical outcomes. The inadequate disease awareness can reduce treatment seeking tendency.

High cost of therapies can hamper the market growth

Effective treatment of acute kidney injury involves renal replacement therapy procedures like hemodialysis and continuous renal replacement therapy which are highly complex and resource intensive. The equipment, disposables, and infrastructure required for dialysis impose substantial financial burden, especially in low and middle-income countries with limited healthcare budgets. Even developed nations face issues of affordability and access to expensive renal replacement modalities. The prohibitive costs associated with current treatment regimens significantly limit their widespread applications, thus, hampering the market growth.

Increasing healthcare expenditure creates lucrative prospects

With rising incomes, more countries are willing and able to devote greater portion of their GDP towards improving healthcare systems. Growing healthcare expenditure in developing economies of Asia, Latin America, Middle East and Africa can drive the market growth. Advanced treatments for acute kidney injury require huge investments which were earlier not feasible. However, improving spending on medical services in emerging nations now offers ample opportunities for existing as well as new market players globally.

Advancements in clinical pathways open new avenues

Continuous efforts are underway to develop novel and more effective solutions to manage acute kidney injury. Promising research pipelines include biomarkers for early diagnosis, pharmacological therapies targeting renal damage pathways and enhanced renal replacement technologies. For instance, biomarkers like NGAL and KIM-1 allow identification of AKI much earlier than conventional tests. Early initiation of appropriate treatment when renal impairment is still mild can significantly improve clinical outcomes. The innovations in diagnostic approaches and therapeutics can revolutionize patient care pathways. This augurs well for the global market by introducing new revenue generation avenues on the horizon.

Link: https://www.coherentmarketinsights.com/market-insight/acute-kidney-injury-treatment-market-4691

Key Developments:

• In February 2024, CalciMedica, Inc., a clinical-stage biopharmaceutical company, received USFDA clearance for its Investigational New Drug (IND) application for Auxora, a small molecule inhibitor targeting Orai1-containing CRAC channels. The company plans to evaluate Auxora in a Phase 2 trial, named KOURAGE, for acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). The trial is expected to begin in the first half of 2024, with data anticipated in 2025.
• In December 2023, Mission Therapeutics received FDA approval for its Investigational New Drug (IND) application for MTX652, its lead asset. This approval allows the company to move forward with its planned Phase II clinical trial in the U.S. MTX652 is a first-in-class therapeutic targeting mitophagy, developed by the clinical-stage biotech company.

Key Player:

Angion Biomedica Corp., AM-Pharma, Quark Pharmaceuticals, Inc., Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., LG Chem, Kringle Pharma, Inc., AstraZeneca, Amgen Inc., Gilead Sciences, Roche, Merck & Co., Inc., Pfizer Inc., Sanofi, Bristol-Myers Squibb, Eli Lilly and Company, Novartis AG, and AbbVie Inc.